Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.

Lu H, Liu C, Velazquez R, Wang H, Dunkl LM, Kazic-Legueux M, Haberkorn A, Billy E, Manchado E, Brachmann SM, Moody SE, Engelman JA, Hammerman PS, Caponigro G, Mohseni M, Hao HX.

Mol Cancer Ther. 2019 May 8. doi: 10.1158/1535-7163.MCT-18-0852. [Epub ahead of print]

PMID:
31068384
2.

NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.

Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, Rudin CM, de Stanchina E, Manchado E, Sherr CJ, Lowe SW.

Science. 2018 Dec 21;362(6421):1416-1422. doi: 10.1126/science.aas9090.

PMID:
30573629
3.

Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.

Álvarez-Fernández M, Sanz-Flores M, Sanz-Castillo B, Salazar-Roa M, Partida D, Zapatero-Solana E, Ali HR, Manchado E, Lowe S, VanArsdale T, Shields D, Caldas C, Quintela-Fandino M, Malumbres M.

Cell Death Differ. 2018 May;25(5):828-840. doi: 10.1038/s41418-017-0024-0. Epub 2017 Dec 11.

4.

Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer.

O'Rourke KP, Loizou E, Livshits G, Schatoff EM, Baslan T, Manchado E, Simon J, Romesser PB, Leach B, Han T, Pauli C, Beltran H, Rubin MA, Dow LE, Lowe SW.

Nat Biotechnol. 2017 Jun;35(6):577-582. doi: 10.1038/nbt.3837. Epub 2017 May 1.

5.

USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.

Fraile JM, Manchado E, Lujambio A, Quesada V, Campos-Iglesias D, Webb TR, Lowe SW, López-Otín C, Freije JM.

J Biol Chem. 2017 Mar 10;292(10):4164-4175. doi: 10.1074/jbc.M116.762757. Epub 2017 Feb 1.

6.

A Pipeline for Drug Target Identification and Validation.

Manchado E, Huang CH, Tasdemir N, Tschaharganeh DF, Wilkinson JE, Lowe SW.

Cold Spring Harb Symp Quant Biol. 2016;81:257-267. doi: 10.1101/sqb.2016.81.031096. Epub 2017 Jan 5. Review.

7.

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, Rosen N, Lowe SW, Scheinberg DA.

Cancer Immunol Res. 2016 Nov;4(11):936-947. Epub 2016 Sep 28.

8.

A combinatorial strategy for treating KRAS-mutant lung cancer.

Manchado E, Weissmueller S, Morris JP 4th, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW.

Nature. 2016 Jun 30;534(7609):647-51. Epub 2016 Jun 22.

9.

Corrigendum: In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.

Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E, Lowe SW, Ventura A.

Nature. 2015 Aug 27;524(7566):502. doi: 10.1038/nature14571. Epub 2015 Jun 24. No abstract available.

PMID:
26106864
10.

In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.

Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E, Lowe SW, Ventura A.

Nature. 2014 Dec 18;516(7531):423-7. doi: 10.1038/nature13902. Epub 2014 Oct 22. Erratum in: Nature. 2015 Aug 27;524(7566):502.

11.

Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice.

Dow LE, Nasr Z, Saborowski M, Ebbesen SH, Manchado E, Tasdemir N, Lee T, Pelletier J, Lowe SW.

PLoS One. 2014 Apr 17;9(4):e95236. doi: 10.1371/journal.pone.0095236. eCollection 2014.

12.

Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.

Weissmueller S, Manchado E, Saborowski M, Morris JP 4th, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, Aust D, Markert EK, Wu J, Grimmond SM, Pilarsky C, Prives C, Biankin AV, Lowe SW.

Cell. 2014 Apr 10;157(2):382-394. doi: 10.1016/j.cell.2014.01.066.

13.

The APC/C cofactor Cdh1 prevents replicative stress and p53-dependent cell death in neural progenitors.

Eguren M, Porlan E, Manchado E, García-Higuera I, Cañamero M, Fariñas I, Malumbres M.

Nat Commun. 2013;4:2880. doi: 10.1038/ncomms3880.

14.

Cdc14b regulates mammalian RNA polymerase II and represses cell cycle transcription.

Guillamot M, Manchado E, Chiesa M, Gómez-López G, Pisano DG, Sacristán MP, Malumbres M.

Sci Rep. 2011;1:189. doi: 10.1038/srep00189. Epub 2011 Dec 12.

15.

Killing cells by targeting mitosis.

Manchado E, Guillamot M, Malumbres M.

Cell Death Differ. 2012 Mar;19(3):369-77. doi: 10.1038/cdd.2011.197. Epub 2012 Jan 6. Review.

16.

Non-mitotic functions of the Anaphase-Promoting Complex.

Eguren M, Manchado E, Malumbres M.

Semin Cell Dev Biol. 2011 Aug;22(6):572-8. doi: 10.1016/j.semcdb.2011.03.010. Epub 2011 Mar 23. Review.

PMID:
21439391
17.

Targeting aneuploidy for cancer therapy.

Manchado E, Malumbres M.

Cell. 2011 Feb 18;144(4):465-6. doi: 10.1016/j.cell.2011.01.037.

18.

Targeting mitotic exit leads to tumor regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55α,δ phosphatase.

Manchado E, Guillamot M, de Cárcer G, Eguren M, Trickey M, García-Higuera I, Moreno S, Yamano H, Cañamero M, Malumbres M.

Cancer Cell. 2010 Dec 14;18(6):641-54. doi: 10.1016/j.ccr.2010.10.028.

19.

The anaphase-promoting complex/cyclosome (APC/C): cell-cycle-dependent and -independent functions.

Manchado E, Eguren M, Malumbres M.

Biochem Soc Trans. 2010 Feb;38(Pt 1):65-71. doi: 10.1042/BST0380065. Review.

PMID:
20074037
20.

Genomic stability and tumour suppression by the APC/C cofactor Cdh1.

García-Higuera I, Manchado E, Dubus P, Cañamero M, Méndez J, Moreno S, Malumbres M.

Nat Cell Biol. 2008 Jul;10(7):802-11. doi: 10.1038/ncb1742. Epub 2008 Jun 15.

PMID:
18552834

Supplemental Content

Loading ...
Support Center